BioMarin settles patent dispute with Ascendis Pharma, stock rises

BioMarin announced a global settlement with Ascendis Pharma, with Ascendis paying royalties on Yuviwel sales; BioMarin's stock jumped on the news.

31 Aug, 06:33 — 31 Aug, 06:33

Post Share

Sources

Showing 1 of 2 sources

morningstar1d ago

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Morningstar

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea Morningstar

Read full article →

Coverage Timeline

First report: morningstar · 31 Aug, 06:33|Full coverage: 2 · 4h|Window: 4h

Left-leaningCenterRight-leaning

morningstar31 Aug, 06:33First to report

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Morningstar

4h later

investing-com31 Aug, 11:02Latest update

BioMarin settles patent dispute with Ascendis Pharma, stock rises

Sources

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Morningstar

Coverage Timeline

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Morningstar

BioMarin stock jumps after Ascendis patent settlement deal

Related Stories

BOJ to debate rate rise, inflation much closer to 2% target: governor

Markets React to Middle East Tensions as Oil Prices Surge and Gold Falls

Apple Announces Executive Compensation Packages for Ternus and Cook

Bessent Urges BOJ Chief to Take Decisive Action to Stabilize Yen